CipherGene Launches 'QingClear' AI-Powered Genomic Data Interpretation Platform and Unveils 'JingCrystal' Precision Medicine Product Line

On October 16, 2016, SafeGene (Beijing) Genomics Technology Co., Ltd. (hereinafter referred to as “SafeGene”) held the “Strategic Launch Conference for the Whole-Genome Data Analysis Platform” in Beijing, announcing the official launch of its intelligent genomic data analysis platform, “QingClear,” and its precision medicine product line, the “JingCrystal” series.

Saifu Gene was established in October 2015, with its headquarters located in Zhongguancun, Beijing. It is a precision medicine service provider specializing in the industrial application of Chinese genomic big data in health management and disease diagnosis and treatment. The founder and CEO of Saifu Gene, Yu Weishi, is a scientist at the National Cancer Institute of the U.S. National Institutes of Health. He has 12 years of extensive research experience in cancer and disease genomics, stem cells, and regenerative medicine, and has accumulated profound insights into the cancer and disease diagnosis and treatment industry.

Three years ago, Yu Weishi assembled a team of 64 technical professionals through a U.S.-based entrepreneurial platform for Ph.D. talent. The majority of the team members hail from prestigious American institutions and leading medical research organizations, including Harvard University, Yale University, the National Institutes of Health (NIH), and the MD Anderson Cancer Center.

Driven by the dream of advancing precision medicine in China, Yu Weishi returned to the country with his team in 2015 to found Safe Gene. The company was successfully selected for the seventh cohort of Microsoft Accelerator, recognized as one of “China’s Best Incubators,” with an acceptance rate of less than 2%, becoming the only gene big data company among the 126 incubated teams at that time.

In February this year, Saifu Gene completed its angel investment round, securing tens of millions of yuan in funding from three firms: “Chuangjian,” “Jiangmen,” and “Langmafeng.”

Yu Weishi believes that “Qing Platform” is China’s first analytical tool focused on whole-genome sequencing data to enable precision diagnosis and treatment of diseases.

Currently, clinical products offered by genetic testing companies on the market predominantly utilize gene chip and gene panel technologies. A limitation of these two methods is that they can only cover known genetic information. In contrast, whole-genome data analysis captures data from approximately 20,000 genes. Therefore, whole-genome analysis is more comprehensive and precise than gene panel analysis, providing more effective support for disease diagnosis and treatment.

The Qing Platform is ultimately designed to establish an AI-driven precision medicine service system that integrates the storage, computation, analysis, and interpretation of large-scale medical data. By consolidating three major databases—cancer-gene, drug-gene, and disease-gene—it enables rapid detection, in-depth annotation, and specialized interpretation of genetic mutations. Leveraging multi-dimensional genetic information and clinical data, the platform generates highly readable bio-clinical interactive reports, characterized by four key attributes: speed, accuracy, stability, and reproducibility.

This platform not only provides optimal solutions for genomic data interpretation but also achieves automation, high-throughput processing, and personalization of genomic analysis through technological advancements. This significantly enhances the accuracy and speed of genomic data interpretation, reduces costs, and enables intelligent genomic analysis.

According to official data provided by SafeGene, the intelligent model can increase interpretation speed by up to 20–50 times compared to manual analysis currently used in the industry. Meanwhile, it has reduced the error rate in pathogenic variant prediction by 19% and improved accuracy by 50%.

Possession of a robust genetic database of the Chinese population, coupled with mastery of core algorithms that enable rapid, accurate, and comprehensive analysis of large-scale genomic data, is considered essential for entering the vast market of China’s precision medicine industry. Currently, SafeGene has already acquired these two capabilities and is rapidly advancing toward the creation of an “Intelligent Genomic Data Analysis Platform.”

Leveraging the Qing platform, SaiFu Gene has also launched the “Jing” series of products, including “Anjing” for epilepsy patients, “Yuanjing” for cancer clinical research, and “Quanjing” for the healthy population.

Among these, the launch of Anjing has enabled China to achieve a major breakthrough—from zero to one—in the precise diagnosis and effective treatment of epilepsy. Its most distinctive feature is the application of whole-genome sequencing technology to assist in the diagnosis and treatment of epilepsy, pioneering a new model for personalized epilepsy care.

“Our precision diagnosis and treatment product for epilepsy, designed specifically for the Chinese population, can be said to be a global first. Our efforts in the field of epilepsy help us establish our own advantages in the realm of precision medicine,” said Yu Weishi.

The second-largest product in the “Jing” series, namely “Yuanjing” for cancer clinical research, primarily focuses on researching upgrade solutions for existing diagnostic, therapeutic, and pharmaceutical products. It is a product developed specifically for cancer clinical research and clinical translation.

“Jing” Series’ Third Product, “Quan Jing,” Primarily Targets Mass Health Management Needs. Customers submit their personalized requirements to Saifu Gene and purchase related testing products and services. After sample collection, customers will receive a genetic analysis-based health management report within 30–40 days, enabling them to benefit for life from a single test.

To date, Saifu Gene has established in-depth collaborations with more than 30 renowned domestic and international medical and research institutions—including the Cleveland Clinic, The Ohio State University College of Medicine, the U.S. National Institutes of Health (NIH), Peking University Cancer Hospital, Peking Union Medical College Hospital, Shanghai Eastern Hepatobiliary Surgery Hospital, Tangdu Hospital of the Fourth Military Medical University, and Xiangya Hospital of Central South University—as well as leading Chinese third-party testing agencies such as Novogene, WuXi AppTec, Genetron Health, and HaploX Biotechnology, focusing on product research and development, production applications, and market promotion.